Back To Schedule
Thursday, June 22 • 10:45am - 12:00pm
#407: Exploration of Metabolic Diseases: Is the Liver the New Heart?

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Session
Level: Intermediate
CE: CME 1.25; IACET 1.25; RN 1.25

With the increasing prevalence of metabolic disease, this session will explore the rising incidence of metabolic disease such as diabetes as well as emerging areas of metabolic diseases such as NAFLD/NASH. With new imaging technique enhancements, we observe previously undetected liver scarring progressing to fibrosis and onto cirrhosis. With no NAFLD/NASH-specific treatment to date, the FDA has provided recommendations in this indication.

Learning Objectives

Discuss why liver fibrosis is becoming a concern in the pharmaceutical industry and is an area needed for therapy.


Clayton Dehn, MS


Liver Let Die: Challenges and Opportunities in Developing Early Interventions for Fatty Liver Disease
Clayton Dehn, MS

Understanding the Natural History and Health Burden of Nonalcoholic Fatty Liver Disease (NAFLD): America’s Newest Epidemic
Naim Alkhouri, MD

Challenges and Opportunities in Clinical Development in Non-Alcoholic Steatohepatitis (NASH): Drugs for NASH Paving the Way
Claudia M. Filozof, DrMed, MD

The DASH to Treat NASH
Melissa Palmer, MD

avatar for Nita Ichhpurani

Nita Ichhpurani

Senior Director, Global Clinical Development, Celerion
24 yrs of pharma experience. At Pharmacia, Nita was a Chemist and PM in Clinical Pharmacology in oncology and CNS research. At MDS, she managed Global Central lab teams and later become the Latin American Lab Manager. At Celerion, she managed drug development programs from discovery... Read More →

avatar for Naim Alkhouri

Naim Alkhouri

Director of the Metabolic Center, Texas Liver Institute
Dr. Naim Alkhouri is the Director of the Metabolic Center at the Texas Liver Institute. He has over 100 publications and presents his work at national and international conferences. His specialty interests include nonalcoholic fatty liver disease and liver transplantation. Among many... Read More →
avatar for Clayton Dehn

Clayton Dehn

Senior Vice President, Early Phase Service and Strategic Development, Clinical Trials of Texas, Inc.
Clayton Dehn is a research physiologist with expertise in metabolic disorders. He is the co-inventor of a process and substance for disturbing the inheritance pattern of ion-channelopathic disorders, and the sole author of the first publication cautioning against the risk of SGLT-inhibition... Read More →
avatar for Claudia Filozof

Claudia Filozof

Executive medical director, Covance Inc.
Executive Medical Director at Covance, Dr Filozof is board certified in Nutrition & Metabolism. Her career spans 20 y in Academia and more than 12 y of service in the Pharma industry. She has worked on NAFLD/NASH projects since 2011 and is an active contributor to the academic NASH... Read More →
avatar for Melissa Palmer

Melissa Palmer

Global Development Lead, NASH, Shire
Dr. Melissa Palmer has been a Hepatologist since 1988 and has been doing research in the field of liver disease since 1983. She has worked in industry in varying leadership roles which have spanned from Pharmacovigilence to Research and Development. She currently works at Shire pharmaceuticals... Read More →

Thursday June 22, 2017 10:45am - 12:00pm CDT
S401d McCormick Place 2301 South Martin Luther King Jr. Drive, Gate 4 Chicago, IL 60616
  07: SpecialPops, Session